FDA Approves Dostarlimab-gxly + Chemotherapy for Endometrial Cancer

On July 31, the US Food and Drug Administration (FDA) approved dostarlimab-gxly with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent endometrial cancer that is mismatch repair deficient, as determined by an FDA-approved test, or microsatellite instability-high.

For more information read the FDA announcement and the GlaxoSmithKline announcement

Posted 8/2/2023